Published in Hepatology on September 01, 2010
Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol (2014) 3.38
Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol (2010) 2.16
Treatment of portal hypertension. World J Gastroenterol (2012) 1.39
UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut (2015) 1.20
Kidneys in chronic liver diseases. World J Gastroenterol (2012) 1.10
Bacterial infections in end-stage liver disease: current challenges and future directions. Gut (2012) 1.00
Management of varices in patients with cirrhosis. Nat Rev Gastroenterol Hepatol (2013) 0.99
Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharmacol Ther (2012) 0.99
Beta-blockers in cirrhosis: friend and foe? Hepatology (2010) 0.96
Portal vein thrombosis in cirrhosis: Controversies and latest developments. World J Gastroenterol (2015) 0.94
Quantitative histological-hemodynamic correlations in cirrhosis. Hepatology (2012) 0.93
Cirrhotic ascites review: Pathophysiology, diagnosis and management. World J Hepatol (2013) 0.91
Beta-blockers in liver cirrhosis. Ann Gastroenterol (2014) 0.90
Beta-blockers have no effect on outcomes in patients with cirrhosis and severe infections. Hepatology (2011) 0.87
Varices and Variceal Hemorrhage in Cirrhosis: A New View of an Old Problem. Clin Gastroenterol Hepatol (2015) 0.86
Improving survival in decompensated cirrhosis. Int J Hepatol (2012) 0.86
Is hydrophobia necessary for the hepatologist prescribing nonselective beta-blockers in cirrhosis? Hepatology (2011) 0.84
Cirrhotic cardiomyopathy. World J Gastroenterol (2015) 0.84
Nonselective beta-blockers in cirrhotic patients with no or small varices: A meta-analysis. World J Gastroenterol (2015) 0.83
Non-selective beta-blockers are not associated with serious infections in veterans with cirrhosis. Aliment Pharmacol Ther (2013) 0.83
The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists. Dig Dis Sci (2011) 0.82
Beta-adrenergic receptor 1 selective antagonism inhibits norepinephrine-mediated TNF-alpha downregulation in experimental liver cirrhosis. PLoS One (2012) 0.81
Paracentesis-induced circulatory dysfunction: a primer for the interventional radiologist. Semin Intervent Radiol (2014) 0.81
Arrhythmia risk in liver cirrhosis. World J Hepatol (2015) 0.79
β-Adrenergic agonist and antagonist regulation of autophagy in HepG2 cells, primary mouse hepatocytes, and mouse liver. PLoS One (2014) 0.79
Beta-blockers in cirrhosis patients with refractory ascites. Hepatology (2014) 0.79
Nonselective β-blockers may induce development of portal vein thrombosis in cirrhosis. World J Gastroenterol (2014) 0.78
The impact of paracentesis flow rate in patients with liver cirrhosis on the development of paracentesis induced circulatory dysfunction. Clin Mol Hepatol (2015) 0.78
Housing Temperature-Induced Stress Is Suppressing Murine Graft-versus-Host Disease through β2-Adrenergic Receptor Signaling. J Immunol (2015) 0.77
Recent advances in cirrhotic cardiomyopathy. Dig Dis Sci (2014) 0.77
Treatment and management of ascites and hepatorenal syndrome: an update. Therap Adv Gastroenterol (2015) 0.77
Recent advances in the management of variceal bleeding. Gastroenterol Rep (Oxf) (2017) 0.76
Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology (2011) 0.76
Is this really the end of beta-blockers in patients with cirrhosis and refractory ascites? Hepatology (2010) 0.76
Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis. BMJ Open (2016) 0.76
Endoscopic management of portal hypertension. Int J Hepatol (2012) 0.76
The deleterious effects of propranolol on patients with cirrhosis. Hepatology (2010) 0.76
Primary Prophylaxis for Variceal Bleeding and the Improved Survival of Patients with Newly Diagnosed Hepatocellular Carcinoma. Dig Dis Sci (2016) 0.76
Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis? Clin Mol Hepatol (2012) 0.76
Portal hypertension: Nonselective β-blockers in patients with refractory ascites. Nat Rev Gastroenterol Hepatol (2010) 0.76
Ascites and spontaneous bacterial peritonitis: recommendations from two United States centers. Saudi J Gastroenterol (2014) 0.76
Is it time to replace propranolol with carvedilol for portal hypertension? World J Gastrointest Endosc (2015) 0.76
I. Beta-blockers: Finding the Right Timing and its Role in Cirrhosis. J Clin Exp Hepatol (2012) 0.75
Use of non-selective beta blockers in cirrhosis: the evidence we need before closing (or not) the window. World J Gastroenterol (2015) 0.75
Future therapy of portal hypertension in liver cirrhosis - a guess. F1000Prime Rep (2014) 0.75
Does cardiac dysfunction explain deleterious effects of beta-blockers in cirrhosis and refractory ascites? Hepatology (2010) 0.75
Are these results trustworthy? A guide for reading the medical literature. Avicenna J Med (2017) 0.75
Use of Non-selective Beta-blockers in Decompensated Cirrhosis: Controversy Continues. J Clin Exp Hepatol (2015) 0.75
A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. Am J Gastroenterol (2016) 0.75
Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension. World J Hepatol (2016) 0.75
Non-selective β-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function. BMJ Open Gastroenterol (2016) 0.75
Beta-blockers in patients with cirrhosis and refractory ascites. Hepatology (2010) 0.75
Effects of beta-blockers on survival for patients with cirrhosis and refractory ascites. Hepatology (2010) 0.75
Facility- and Patient-Level Factors Associated with Esophageal Variceal Screening in the USA. Dig Dis Sci (2015) 0.75
Repurposing of approved cardiovascular drugs. J Transl Med (2016) 0.75
Management of cirrhotic ascites. Ther Adv Chronic Dis (2015) 0.75
Early liver transplantation for severe alcoholic hepatitis. N Engl J Med (2011) 8.50
Clinical classification of pulmonary hypertension. J Am Coll Cardiol (2004) 5.87
Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology (2012) 5.75
Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology (2007) 3.75
Acute-on chronic liver failure. J Hepatol (2012) 3.74
Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology (2007) 3.61
The "50-50 criteria" on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg (2005) 3.46
Amanita phalloides poisoning: reassessment of prognostic factors and indications for emergency liver transplantation. J Hepatol (2006) 3.14
The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology (2003) 3.00
Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology (2009) 2.97
Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology (2010) 2.82
Albumin administration improves organ function in critically ill hypoalbuminemic patients: A prospective, randomized, controlled, pilot study. Crit Care Med (2006) 2.74
Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut (2011) 2.65
Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol (2011) 2.59
Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology (2003) 2.57
Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol (2010) 2.43
Portal cavernoma-associated cholangiopathy: a clinical and MR cholangiography coupled with MR portography imaging study. Hepatology (2003) 2.43
EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol (2003) 2.37
Severe sepsis in cirrhosis. Hepatology (2009) 2.33
Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int (2010) 2.32
TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology (2008) 2.25
Prospective comparison of spleen and liver stiffness by using shear-wave and transient elastography for detection of portal hypertension in cirrhosis. Radiology (2014) 2.22
The evaluation of renal function and disease in patients with cirrhosis. J Hepatol (2010) 2.10
Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology (2002) 2.06
Autophagy in liver diseases. J Hepatol (2010) 2.06
Risk factors for Enterobacteriaceae bacteremia after liver transplantation. Transpl Int (2008) 2.06
Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res (2013) 2.05
Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg (2003) 2.03
Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol (2004) 2.01
Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology (2012) 2.01
IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol (2011) 1.97
Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA (2013) 1.94
Indications, timing, and techniques of tracheostomy in 152 French ICUs. Chest (2005) 1.94
Cirrhotic patients in the medical intensive care unit: early prognosis and long-term survival. Crit Care Med (2010) 1.94
CD40 ligand+ microparticles from human atherosclerotic plaques stimulate endothelial proliferation and angiogenesis a potential mechanism for intraplaque neovascularization. J Am Coll Cardiol (2008) 1.82
Microbial epidemiology and outcome of bloodstream infections in liver transplant recipients: an analysis of 259 episodes. Liver Transpl (2010) 1.81
Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. Hepatology (2007) 1.81
Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology (2014) 1.81
The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver Int (2009) 1.76
Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med (2008) 1.71
The Multiple Organ Dysfunction Score (MODS) versus the Sequential Organ Failure Assessment (SOFA) score in outcome prediction. Intensive Care Med (2002) 1.71
A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology (2009) 1.70
Abnormal plasma microparticles impair vasoconstrictor responses in patients with cirrhosis. Gastroenterology (2012) 1.69
Management of critically-ill cirrhotic patients. J Hepatol (2012) 1.65
Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis. Hepatology (2012) 1.64
Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases. Kidney Int (2011) 1.64
Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology (2015) 1.62
Management of hepatic vascular diseases. J Hepatol (2012) 1.61
Septic shock of early or late onset: does it matter? Chest (2004) 1.58
The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab Invest (2003) 1.57
Histologic scoring of liver biopsy in focal nodular hyperplasia with atypical presentation. Hepatology (2002) 1.55
Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PLoS One (2010) 1.54
High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats. Hepatology (2007) 1.50
Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol (2007) 1.49
Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology (2005) 1.48
Endothelial cell-derived microparticles loaded with iron oxide nanoparticles: feasibility of MR imaging monitoring in mice. Radiology (2012) 1.46
Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood (2003) 1.45
Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology (2003) 1.42
Noninvasive assessment of portal hypertension in patients with cirrhosis. Hepatology (2011) 1.42